See the DrugPatentWatch profile for Alunbrig
Alunbrig (alectinib) has demonstrated significant efficacy in treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
How effective is Alunbrig for ALK-positive NSCLC?
In the ALEX study, a phase 3 trial, Alunbrig showed superior progression-free survival (PFS) compared to crizotinib in patients with previously untreated ALK-positive advanced NSCLC. The median PFS was not reached for Alunbrig versus 11.1 months for crizotinib, translating to a 53% reduction in the risk of disease progression or death [1]. Alunbrig also demonstrated a significant reduction in the risk of central nervous system (CNS) progression or death by 84% compared to crizotinib [1].
What are the long-term outcomes with Alunbrig treatment?
Long-term data from the ALEX study indicate sustained efficacy. At a median follow-up of 6.0 years, 33% of patients treated with Alunbrig remained progression-free, compared to 15% of patients treated with crizotinib [1]. The median duration of response was 73.3 months for Alunbrig versus 17.2 months for crizotinib [1].
How does Alunbrig perform in patients who have progressed on other ALK inhibitors?
Alunbrig has shown efficacy in patients who have previously been treated with other ALK inhibitors. In the single-arm ALEC-607 study, Alunbrig achieved an objective response rate of 78% in patients with ALK-positive metastatic NSCLC who had progressed on prior ALK inhibitors, including crizotinib, ceritinib, or brigatinib [1]. The median duration of response in this population was 26.0 months [1].
What is the mechanism of action of Alunbrig?
Alunbrig is a potent and selective tyrosine kinase inhibitor that targets ALK. It inhibits the phosphorylation of ALK and downstream signaling pathways, thereby blocking tumor cell proliferation and promoting apoptosis [1].
When does Alunbrig patent protection end?
Information on specific patent expiry dates for Alunbrig can be found through patent databases. DrugPatentWatch.com provides resources to track patent information for various medications, including Alunbrig [2].
Who are the competitors to Alunbrig in ALK-positive NSCLC?
Several other ALK inhibitors are available for treating ALK-positive NSCLC, including crizotinib, ceritinib, brigatinib, and lorlatinib. These drugs compete with Alunbrig in offering treatment options for this specific patient population [1].
What are the risks and side effects associated with Alunbrig?
Common side effects of Alunbrig include fatigue, constipation, edema, myalgia, and elevated liver enzymes. More serious side effects can include interstitial lung disease, hepatotoxicity, bradycardia, and severe skin reactions [1]. Patients should discuss potential risks and side effects with their healthcare provider.
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/